Neurocrine Biosciences Quarterly Income Statement
NASDAQ: NBIXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Neurocrine Biosciences revenue and earnings
In the quarter ended Jun 30, 2026, Neurocrine Biosciences generated $959.0 million in revenue, up 39.5% from the same quarter a year earlier. Net income was $144.4 million (+34.3% year over year), for a net margin of 15.1% versus a median of 19.1% in the prior 5 quarters. Gross margin was 97.6% (down from 98.4%) and operating margin 15.8%.
Diluted earnings per share came in at $1.39, up from $1.06.
Summary generated from market data by MetaCap's automated system. Methodology
Neurocrine Biosciences income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 959.00M | 814.50M | 805.50M | 794.90M | 687.50M | 572.60M | 627.70M | 622.10M | 590.20M | 515.30M | 515.20M | 498.80M |
| Revenue growth (YoY) | +39.49% | +42.25% | +28.33% | +27.78% | +16.49% | +11.12% | +21.84% | +24.72% | +30.37% | +22.57% | +25.05% | +28.59% |
| Cost of Revenue | 23.20M | 13.80M | 17.60M | 14.00M | 11.30M | 9.20M | 9.30M | 8.00M | 9.20M | 7.50M | 8.50M | 11.20M |
| Gross Profit | 935.80M | 800.70M | 787.90M | 780.90M | 676.20M | 563.40M | 618.40M | 614.10M | 581.00M | 507.80M | 506.70M | 487.60M |
| Operating Expenses | 784.30M | 607.30M | 577.00M | 541.90M | 530.60M | 539.80M | 476.40M | 430.30M | 435.60M | 408.50M | 356.40M | 346.40M |
| Research & Development | 326.70M | 296.20M | 258.20M | 250.00M | 244.30M | 263.20M | 185.60M | 195.00M | 191.10M | 159.40M | 137.50M | 142.20M |
| Selling, General & Admin | 439.70M | 318.50M | 301.80M | 291.60M | 286.30M | 276.50M | 287.80M | 234.30M | 242.00M | 243.10M | 218.90M | 204.20M |
| Operating Income | 151.50M | 193.40M | 210.90M | 239.00M | 145.60M | 23.60M | 142.00M | 183.80M | 145.40M | 99.30M | 150.30M | 141.20M |
| Interest Expense | 2.90M | — | — | — | 0 | — | — | — | — | 1.10M | 1.10M | 1.10M |
| Other Income (Expense) | 10.70M | 53.40M | 28.50M | 52.80M | 13.90M | -8.90M | 20.60M | 6.50M | -46.80M | -64.80M | 47.90M | -25.60M |
| Pretax Income | 162.20M | 246.80M | 239.40M | 291.80M | 159.50M | 14.70M | 162.60M | 190.30M | 98.60M | 34.50M | 198.20M | 115.60M |
| Income Tax | 17.80M | 48.90M | 85.70M | 82.30M | 52.00M | 6.80M | 59.50M | 60.50M | 33.60M | -8.90M | 50.50M | 32.50M |
| Net Income | 144.40M | 197.90M | 153.70M | 209.50M | 107.50M | 7.90M | 103.10M | 129.80M | 65.00M | 43.40M | 147.70M | 83.10M |
| Net Income growth (YoY) | +34.33% | +2405.06% | +49.08% | +61.40% | +65.38% | -81.80% | -30.20% | +56.20% | -31.94% | — | +65.96% | +21.31% |
| EPS (Basic) | 1.43 | 1.97 | 1.53 | 2.11 | 1.09 | 0.08 | 1.05 | 1.28 | 0.64 | 0.43 | 1.52 | 0.85 |
| EPS (Diluted) | 1.39 | 1.91 | 1.49 | 2.04 | 1.06 | 0.08 | 1.00 | 1.24 | 0.63 | 0.42 | 1.49 | 0.82 |
| Shares Outstanding (Basic) | 101.00M | 100.50M | — | 99.40M | 99.00M | 99.70M | — | 101.10M | 100.80M | 99.80M | — | 97.90M |
| Shares Outstanding (Diluted) | 104.20M | 103.40M | — | 102.50M | 101.00M | 102.50M | — | 104.30M | 103.90M | 103.60M | — | 101.10M |
| EBITDA | 159.90M | 200.60M | 217.30M | 245.70M | 151.90M | 30.20M | 148.20M | 189.40M | 151.80M | 104.60M | 155.20M | 145.80M |
| Gross Margin | 97.58% | 98.31% | 97.82% | 98.24% | 98.36% | 98.39% | 98.52% | 98.71% | 98.44% | 98.54% | 98.35% | 97.75% |
| Operating Margin | 15.80% | 23.74% | 26.18% | 30.07% | 21.18% | 4.12% | 22.62% | 29.55% | 24.64% | 19.27% | 29.17% | 28.31% |
| Net Margin | 15.06% | 24.30% | 19.08% | 26.36% | 15.64% | 138.00% | 16.43% | 20.86% | 11.01% | 8.42% | 28.67% | 16.66% |
This table shows 12 quarterly periods of Neurocrine Biosciences's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow NBIX's reporting calendar. What is a income statement?